1 day ago
Symbiotec Pharmalab Shares Debut Near Issue Price, Recover Later
Symbiotec Pharmalab is a company that makes pharmaceutical ingredients and other specialised products.
Its shares began trading on the stock market on September 1.
On the BSE, the shares started slightly below their IPO price.
On the NSE, they started exactly at the IPO price.
The price moved up and down during the day.
Later, it traded well above the IPO price on both exchanges.
Investors had shown strong demand for the IPO before trading began.
The company plans to use money from the new shares mainly to repay loans and for general business needs.
Symbiotec Pharmalab shares listed at ₹978.20 on the BSE, a 0.99% discount to the ₹988 IPO price.
The shares debuted at ₹988 on the NSE, matching the issue price.
After early volatility, the stock reached ₹1,074.05 on the BSE and ₹1,083.40 on the NSE.
The IPO raised ₹1,757 crore through a ₹150 crore fresh issue and a ₹1,607 crore offer for sale.
Reported final IPO subscription differed between sources, at 71.26 times in one account and 75 times in another.
- Who
- Symbiotec Pharmalab, an Indore-based pharmaceutical and biotechnology company.
- What
- The company’s shares made their stock market debut after an IPO.
- Where
- The shares were listed on the BSE and NSE.
- When
- Tuesday, September 1; the IPO bidding ran from August 24 to August 27.
- Why
- The IPO raised funds through a fresh share issue, primarily for loan repayment and general corporate purposes.
Positive Signals
Cautious Signals
Post-listing performance
Positive Signals
The shares recovered from early weakness and later traded 8.70% above the issue price on the BSE and 9.65% above it on the NSE.
Cautious Signals
The BSE debut was subdued, with the stock listing 0.99% below the IPO price and experiencing early highs and lows.
Investor expectations
Positive Signals
The IPO attracted strong demand, with reported final subscription of either 71.26 times or 75 times, depending on the source.
Cautious Signals
The listing fell short of grey-market expectations: a reported ₹185 premium had suggested a potential listing near ₹1,173, or about 19% above the issue price.
Business outlook
Positive Signals
Symbiotec operates across organic chemistry, biotechnology and complex injectables and serves domestic and international markets.
Cautious Signals
The company’s reported profit attributable to owners declined from ₹100.18 crore in FY24 to ₹96.78 crore in FY25 before rising to ₹109.88 crore in FY26.
Key facts
- IPO issue price
- ₹988 per equity share
- BSE listing
- ₹978.20, or 0.99% below the issue price
- NSE listing
- ₹988, in line with the issue price
- Later reported highs
- ₹1,074.05 on the BSE and ₹1,083.40 on the NSE
- Total issue size
- ₹1,757 crore
- Fresh issue
- ₹150 crore
- Offer for sale
- ₹1,607 crore
- Market capitalisation after debut
- ₹6,965.36 crore
Sources
Related news
Symbiotec Pharmalab Shares Set for Premium Market Debut
Symbiotec Pharmalab IPO Draws Strong, Conflicting Subscription Figures
Symbiotec Pharmalabs IPO Opens With 42% Grey-Market Premium
Symbiotec Pharmalab IPO Opens With ₹1,757 Crore Offer
PVR Inox Buyback: September 3 Last Day to Buy
Augmont Enterprises Rises Despite Gold-Buying Appeal and Market Risks
BSE Shares Fall as New Closing Auction Session Draws Scrutiny
Spice Lounge Food Works Stock Hits Upper Circuit Amid Crash
Indian Stocks Slide as Oil, Conflict and Yields Rise
